Myst Therapeutics (Myst), a preclinical stage biotechnology firm targeted on creating chosen TIL-based autologous T cell (PuriT™) remedy merchandise for most cancers, introduced the appointment of George Smith, PhD, MBA as Vice President of Business Operations. Dr. Smith, who brings to Myst over 20 years of profitable drug improvement expertise at each biotechnology and international pharmaceutical firms, was beforehand the founder and lead for the Cell and Gene Therapy Center and Senior Director Portfolio and Innovation at IQVIA. Prior to IQVIA, he led R&D applications at Pfizer for 14 years and constructed a number of profitable start-ups.

“Dr. Smith’s vast experience in drug development from conception to approval will be instrumental to advancing Myst’s PuriT™ products through multi-center clinical trials and on to registration,” stated TJ Langer President and Chief Executive Officer of Myst Therapeutics. “We are very pleased to welcome him to the Myst management team.”

At IQVIA, George based and constructed the Cell and Gene Therapy Center, a gaggle of cell and gene remedy (CAGT) specialists targeted on preclinical, scientific and industrial improvement of CAGT therapeutics. He additionally led due diligence applications. Prior to IQVIA, he led R&D applications, scientific teams and translational medication for the Antiviral and Therapeutic Vaccine Therapeutic Areas at Pfizer. He has helped construct a number of profitable start-ups, together with Althea Technologies and K2 Biopharma. George is at the moment on the advisory board for Visicell Medical. “The innovative PuriT™ approach shows tremendous potential for inducing significant and durable remissions,” stated Dr. Smith. “Myst has a promising product pipeline and a very experienced management team. I am thrilled to join them in developing this new cancer modality.”

VB Transform 2020 Online – July 15-17, 2020: Join main AI executives at VentureBeat’s AI occasion of the 12 months. Register today and save 30% off digital entry passes.

Dr. Smith obtained his Doctorate from the University of California, San Diego primarily based on his work on the Salk Institute and his MBA from the Rady School of Business at UCSD. He is an creator of over 10 peer-review publications and has been a speaker at over 50 conferences.

About the PuriT™ Platform

Clinical proof has demonstrated {that a} sufferers’ tumor infiltrating lymphocytes (TIL) acknowledge tumor particular molecules, site visitors to the tumor, reply to tumor antigen, and selectively eradicate tumors. Clinical research utilizing these cells have proven sturdy goal scientific responses in sufferers with superior metastatic illness, together with refractory melanoma, breast, cervical, and colorectal most cancers. Myst’s PuriT™ platform builds on these successes by enriching and rejuvenating TIL to additional enhance responses. These encouraging outcomes spotlight PuriT™ as an rising modality able to offering customized remedy choices for sufferers spanning a broad spectrum of ailments.

About Myst Therapeutics

Myst Therapeutics Inc. is a privately held, pre-clinical stage biotechnology firm targeted on the event and commercialization of novel most cancers immunotherapy merchandise designed to harness the facility of a affected person’s personal immune system to deal with stable tumors. Myst is creating applied sciences to allow, scale and enhance adoptive cell therapies with a deal with bettering clinically efficient neoantigen enriched T cell therapies for stable tumors. Myst has mixed strategies of figuring out neoantigen reactive T cells from tumor infiltrating lymphocytes (TIL) with Myst’s proprietary applied sciences and experience within the improvement and manufacturing of cell therapies. We imagine this mix will allow Myst to quickly advance and commercialize extremely promising and progressive therapies, addressing a variety of superior stable tumors.

Myst Therapeutics Appoints George Smith as Vice President of Business Operations

View supply model on businesswire.com: https://www.businesswire.com/news/home/20200504005109/en/

Myst Therapeutics
Investor Relations
TJ Langer
[email protected]